Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith & Nephew : Outgoing Smith & Nephew CEO signs off with a downgrade

05/03/2018 | 04:42am EST

LONDON (Reuters) - Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker.

Shares in the British company fell 7 percent after it said underlying revenue for the year would rise by 2-3 percent, less than the 3-4 percent predicted in February.

It also lowered trading profit forecasts, predicting a margin at or above the level achieved last year rather than the 30-70 basis point growth it had targeted.

Bohuon, who steps down on Monday, said the business had seen a "mixed performance" in the quarter to end-March, with established markets like the United States and Europe down 2 percent on an underlying basis and emerging markets up 9 percent, resulting in a flat result overall.

He said the disappointing performance was mainly because of market weakness, citing changing insurance patterns in the United States and budget constraints in Europe hitting elective surgery volumes in Europe.

Britain's state-run health service cancelled some operations at the start of the year because of a shortage of capacity for example.

Bohuon said trading had picked up since the quarter end.

"I see an improving trend; April is showing much better trading and coming back to normal levels, much better than we have seen in January, February and March," he told reporters.

Other areas of weakness included its advanced wound bioactives business, which focuses on difficult-to-treat wounds, where revenue was down 12 percent.

Analyst Kit Lee at Jefferies, who has a "buy" rating on the company, said the divisional trends were familiar but there were more negative than positives in the update.

Bohuon will be replaced by Namal Nawana, who most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott in 2017.

The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.

It is a constant presence on analysts' lists of potential takeovers, with speculation that it could be acquired by a U.S. competitor such as Stryker or be broken up

The company reported first-quarter revenue of $1.2 billion, up 5 percent on a reported basis thanks to foreign exchange tailwinds of 5 percent.

(Reporting by Paul Sandle; editing by Kate Holton/David Evans)

By Paul Sandle

© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
SMITH & NEPHEW PLC -1.35% 1613 Delayed Quote.8.28%
STRYKER CORPORATION -3.12% 230.43 Delayed Quote.-2.87%
All news about SMITH & NEPHEW PLC
07:54aSMITH & NEPHEW : Hall of Fame Health, Smith+Nephew to collaborate on ex-players ..
06:40aSMITH & NEPHEW : +Nephew's PICO◊ Single Use Negative Pressure Wound Therapy ..
01/26SMITH & NEPHEW : Hall of Fame Health, Smith+Nephew to collaborate on ex-players'..
01/25SETTING THE STAGE : Court Sets Oral Argument In Arthrex Cases
01/19European ADRs Move Higher in Tuesday Trading
01/12European ADRs Move Higher in Tuesday Trading
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
01/11European ADRs Move Sharply Lower in Monday Trading
01/11SMITH & NEPHEW : Warns of Revenue, Margin Hit for 2020
01/11SMITH & NEPHEW : Expects Q4, FY20 Revenue Drop On Lower Sales, Volumes Amid COVI..
More news
Financials (USD)
Sales 2020 4 582 M - -
Net income 2020 373 M - -
Net Debt 2020 1 650 M - -
P/E ratio 2020 55,7x
Yield 2020 1,26%
Capitalization 19 664 M 19 612 M -
EV / Sales 2020 4,65x
EV / Sales 2021 3,94x
Nbr of Employees 17 500
Free-Float 98,7%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 23,48 $
Last Close Price 22,47 $
Spread / Highest target 21,5%
Spread / Average Target 4,50%
Spread / Lowest Target -19,6%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors